Pinto Patricia, Ghosh Kanjaksha, Shetty Shrimati
Blood Cells Mol Dis. 2014 Sep;53(3):161-3. doi: 10.1016/j.bcmd.2014.04.007. Epub 2014 May 11.
FVIII inhibitor development in haemophilia A (HA) patients, especially those with severe manifestations is a serious adverse effect in patients with haemophilia A, and the clinical management of these patients is very difficult as most don't respond to conventional treatment. Many genetic and non-genetic risk factors have been proposed however, these are diverse in different population groups, highlighting the importance of determining specific risk factors for each population. F8 mutations and especially inversions, which are the most common causative mutation in severe HA, have been significantly associated with inhibitor development earlier, however there is no conclusive data so far with regard to Indian haemophiliacs. This study provides novel evidence that intron 22 inversions in the F8 gene are indeed significantly associated with FVIII inhibitor development in Indian haemophiliacs. Further studies with other risk factors would enable better insights into the immune response towards FVIII in these patients, and possibly help to characterize patients at a higher risk for inhibitor development.
A型血友病(HA)患者,尤其是那些有严重症状的患者,出现FVIII抑制剂是A型血友病患者的一种严重不良反应,而且这些患者的临床管理非常困难,因为大多数患者对传统治疗没有反应。虽然已经提出了许多遗传和非遗传风险因素,但是这些因素在不同人群中各不相同,这凸显了为每个人群确定特定风险因素的重要性。F8突变,尤其是倒位,是严重HA中最常见的致病突变,与抑制剂的早期出现显著相关,然而,到目前为止,关于印度血友病患者尚无确凿数据。本研究提供了新的证据,表明F8基因内含子22倒位确实与印度血友病患者FVIII抑制剂的出现显著相关。对其他风险因素的进一步研究将有助于更好地了解这些患者对FVIII的免疫反应,并可能有助于确定抑制剂出现风险较高的患者特征。